Strs Ohio Has $596,000 Position in Cogent Biosciences, Inc. $COGT

Strs Ohio boosted its position in Cogent Biosciences, Inc. (NASDAQ:COGT) by 591.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 41,500 shares of the technology company’s stock after buying an additional 35,500 shares during the quarter. Strs Ohio’s holdings in Cogent Biosciences were worth $596,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Emerald Advisers LLC bought a new position in shares of Cogent Biosciences during the 2nd quarter worth approximately $10,381,000. Emerald Mutual Fund Advisers Trust acquired a new position in Cogent Biosciences during the second quarter worth $6,429,000. Saturn V Capital Management LP grew its position in Cogent Biosciences by 55.2% in the second quarter. Saturn V Capital Management LP now owns 2,297,524 shares of the technology company’s stock valued at $16,496,000 after purchasing an additional 817,504 shares in the last quarter. Nantahala Capital Management LLC increased its stake in Cogent Biosciences by 96.3% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,655,689 shares of the technology company’s stock valued at $11,888,000 after buying an additional 812,200 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. lifted its position in Cogent Biosciences by 85.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,734,601 shares of the technology company’s stock worth $12,454,000 after buying an additional 798,025 shares in the last quarter.

Cogent Biosciences Stock Down 1.9%

COGT stock opened at $37.65 on Friday. Cogent Biosciences, Inc. has a 1-year low of $3.72 and a 1-year high of $43.73. The business’s 50 day simple moving average is $38.36 and its 200 day simple moving average is $23.31. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $5.36 billion, a PE ratio of -22.96 and a beta of 0.50.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings data on Monday, November 3rd. The technology company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.04. As a group, research analysts anticipate that Cogent Biosciences, Inc. will post -2.42 EPS for the current year.

Analyst Upgrades and Downgrades

COGT has been the subject of several analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price objective on shares of Cogent Biosciences in a report on Monday, December 8th. Stifel Nicolaus upgraded Cogent Biosciences from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Monday, November 10th. Wall Street Zen upgraded Cogent Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. HC Wainwright increased their price objective on Cogent Biosciences to $52.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cogent Biosciences in a report on Monday, December 8th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cogent Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $39.55.

Insider Activity at Cogent Biosciences

In other Cogent Biosciences news, Director Fairmount Funds Management Llc sold 3,500,000 shares of the stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $36.40, for a total value of $127,400,000.00. Following the transaction, the director directly owned 5,503,418 shares of the company’s stock, valued at $200,324,415.20. This represents a 38.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jessica Sachs sold 82,642 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $38.70, for a total transaction of $3,198,245.40. Following the sale, the insider owned 133,938 shares of the company’s stock, valued at $5,183,400.60. This trade represents a 38.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,737,642 shares of company stock worth $136,600,345 in the last quarter. Corporate insiders own 7.29% of the company’s stock.

Cogent Biosciences Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.